Welcome to Dividends Inside
Welcome to Dividends Inside!

The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.

Banco Santander SA

SAN
$11.78 (- $0.04 - 0.34%)
Last updated: Previous Close (2026-05-19)
SAN Metrics
Exchange
🇺🇸 NYSE XNYS
New York Stock Exchange, Inc.United StatesAmerica/New_York
SectorFinancial Services
IndustryBanks - Diversified
ISINUS05964H1059
Market Price11.78
Dividend Yield 3.59%
Dividend Growth
1Y +23.36%
3Y +44.28%
5Y -9.29%
10Y -15.56%
Annual Dividend 0.19
Latest Payout ($)0.11
Latest Payout Date2026-05-08
Dividend FrequencyQuarterly
P/E Ratio9.62
EPS1.0
Market Cap$180.8B
Book Value8.03
Price to Book1.471
Beta-0.3
52w High13.24
52w Low7.61
Next Earnings Date2026-07-28
About the Company
Banco Santander S.A. Sponsored ADR represents shares in Banco Santander, S.A., a major multinational banking group headquartered in Madrid, Spain. The bank provides a comprehensive range of financial products and services to individuals, small and medium-sized enterprises, large corporations, and public entities across multiple geographies. It operates through key segments including Retail & Commercial Banking, Digital Consumer Bank, Corporate & Investment Banking, Wealth Management & Insurance, and Payments. Offerings encompass demand and time deposits, mutual funds, current and savings accounts, mortgages, consumer finance, loans, credit and debit cards, real estate loans, project finance, debt capital markets, global transaction banking, private banking, mergers and acquisitions advice, asset and risk management, as well as digital payments and mobile/online banking solutions. Banco Santander maintains a strong presence in retail and commercial banking, with significant operations in Latin America—particularly Brazil—continental Europe like Spain and Portugal, the UK, and the US, where it focuses on vehicle finance and regional banking in the Northeast. This diversified structure positions it as a key player in global diversified banking.
Price History
Latest News for SAN
Regional REIT Q4 Earnings Call Highlights
Regional REIT (LON:RGL) executives told investors its 2025 full-year performance was shaped by a challenging operating backdrop and a slower-than-expected leasing market, but said the company made progress on key strategic priorities including asset sales, refinancing, and portfolio repositioning.
Sanofi Autoimmune Pipeline Grows As Market Weighs Valuation And Momentum
Sanofi has secured global exclusive rights to Kali Therapeutics' trispecific antibody KT501 for autoimmune diseases, including a first in human program for rheumatoid arthritis. The company has also received Japanese approval for Dupixent in bullous pemphigoid, making it the first targeted therapy for this condition in Japan. These two developments come as Sanofi, ticker ENXTPA:SAN, trades around €77.77, with the share price showing a 1.1% return over the past week and a 13.0% return over...
Linea Energy Closes Project Debt Financing for Watertown Solar in Michigan
Linea Energy ("Linea"), a U.S. based renewable energy developer and independent power producer ("IPP"), that is sponsored by EnCap Investments L.P. ("EnCap"), announced today that it has closed project financing for its Watertown solar project ("Watertown"). Watertown is a 172 MWdc utility-scale solar energy facility located in Sanilac County, Michigan.
Doral Renewables Secures Nearly $900 Million of Financing Commitments for Construction of Cold Creek Solar + Storage Project
Doral Renewables LLC ("Doral"), a leading, U.S. utility-scale solar and battery storage developer and independent power producer, announced today the successful financial close for the Cold Creek Solar + Storage project in Schleicher and Tom Green Counties in Texas.
Press release: Availability of the Q1 2026 aide-mémoire
Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First quarter 2026 results (sanofi.com) Prepared each quarter, this document is intented to support financial modelling of the quarterly results. It covers non-comparable items, foreign currency impact, and share count. Sanofi's Q1 2026 results will be published on April 23, 2026. About Sanofi Sanofi is an R
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesions BP is the seventh approved indication for Dupixent in Japan TARRYTOWN, N.Y. and PARIS, March 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,